Histone hypoacetylation and increased histone deacetylases in peripheral blood mononuclear cells from patients with Graves' disease

Molecular and Cellular Endocrinology

Volumn 414, Issue , 2015, Pages 143-147

  Yan, Ni ^a   Zhou, Jiao Zhen ^b   Zhang, Jin An ^a   Cai, Tiantian ^b   Zhang, Wen ^b   Wang, Yuan ^b   Muhali, Fatuma Said ^b   Guan, Lijuan ^b   Song, Rong Hua ^a  

^a JINSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Graves' disease (GD); Histone acetylation; Histone modifications; Peripheral blood mononuclear cells (PBMCs)

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; E1A ASSOCIATED P300 PROTEIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE H3; HISTONE H4; MESSENGER RNA; SIRTUIN 1; CREBBP PROTEIN, HUMAN; HDAC1 PROTEIN, HUMAN; HDAC2 PROTEIN, HUMAN; HISTONE; HISTONE ACETYLTRANSFERASE PCAF; SIRT1 PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GRAVES DISEASE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; ACETYLATION; BLOOD; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; MONONUCLEAR CELL;

ACETYLATION; ADULT; CREB-BINDING PROTEIN; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION; GRAVES DISEASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONES; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; P300-CBP TRANSCRIPTION FACTORS; SIRTUIN 1;

EID: 84938856998     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.05.037     Document Type: Article

References (32)

1. Bahn R.S. Graves' ophthalmopathy. N. Engl. J. Med. 2010, 362:726-738.
2. Benvenga S., Guarneri F., Vaccaro M., Santarpia L., Trimarchi F. Homologies between proteins of Borrelia burgdorferi and thyroid autoantigens. Thyroid 2004, 14:964-966.
3. Blanchard F., Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?. Drug Discov. Today 2005, 10:197-204.
4. Brent G.A. Clinical practice. Graves' disease. N. Engl. J. Med. 2008, 358:2594-2605.
5. Brix T.H., Kyvik K.O., Christensen K., Hegedüs L. Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts. J. Clin. Endocrinol. Metab. 2001, 86:930-934.
6. Eschler D.C., Hasham A., Tomer Y. Cutting edge: the etiology of autoimmune thyroid diseases. Clin. Rev. Allerg. Immunol. 2011, 41:190-197.
7. Guarneri F., Benvenga S. Environmental factors and genetic background that interact to cause autoimmune thyroid disease. Curr. Opin. Endocrinol. Diabetes Obes. 2007, 14:398-409.
8. Hasham A., Tomer Y. Genetic and epigenetic mechanisms in thyroid autoimmunity. Immunol. Res. 2012, 54:204-213.
9. Huber L.C., Brock M., Hemmatazad H., Giger O.T., Moritz F., Trenkmann M., et al. Histone deacety-lase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum. 2007, 56:1087-1093.
10. Hu N., Qiu X., Luo Y., Yuan J., Li Y., Lei W., et al. Abnormal histone modification patterns in lupus CD4+ T cells. J. Rheumatol. 2008, 35:804-810.
11. Jungel A., Ospelt C., Gay S. What can we learn from epigenetics in the year 2009?. Curr. Opin. Rheumatol. 2010, 22:284-292.
12. Karouzakis E., Gay R.E., Gay S., Neidhart M. Epigenetic control in rheumatoid arthritis synovial fibroblasts. Nat. Rev. Rheumatol. 2009, 5:266-272.
13. Kitada M., Koya D. SIRT1 in type 2 diabetes: mechanisms and therapeutic potential. Diabetes Metab. J. 2013, 37:315-325.
14. Luo S., Liang G., Zhang P., Zhao M., Lu Q. Aberrant histone modifications in peripheral blood mononuclear cells from patients with Henoch-Schönlein purpura. Clin. Immunol. 2013, 146:165-175.
15. Menconi F., Marcocci C., Marinò M. Diagnosis and classification of Graves' disease. Autoimmun. Rev. 2014, 13:398-402.
16. Miao C.G., Yang Y.Y., He X., Li J., et al. New advances of DNA methylation and histone modifications in rheumatoid arthritis, with special emphasis on MeCP2. Cell. Signal 2013, 25:875-882.
17. Nyström H.F., Jansson S., Berg G., Nyström H.F. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden(Gothenburg) 2003-2005. Clin. Endocrinol. Oxf. 2013, 78:768-776.
18. Sawalha A.H., Jeffries M., Webb R., Lu Q., Gorelik G., Ray D., et al. Defective T-cell ERK signaling induces interferon-regulated gene expression and over-expression of methylation-sensitive genes similar to lupus patients. Genes. Immun. 2008, 9:368-378.
19. Stefan M., Jacobson E.M., Huber A.K., Greenberg D.A., Li C.W., Skrabanek L., et al. Novel variant of thyroglobulin promoter triggers thyroid autoimmunity through an epigenetic interferon α -modulated mechanism. J. Biol. Chem. 2011, 286:31168-33179.
20. Tegla C.A., Azimzadeh P., Andrian-Albescu M., Martin A., Cudrici C.D., Trippe R., et al. SIRT1 is decreased during relapses in patients with multiple sclerosis. Exp. Mol. Pathol. 2014, 96:139-148.
21. Tikoo K., Meena R.L., Kabra D.G., Gaikwad A.B. Change in post-translational modifications of histone H3, heat-shock protein-27 and MAP kinase p38 expression by curcumin streptozotocin induced type I diabetic nephropathy. Br. J. Pharmacol. 2008, 153:1225-1231.
22. Toussirot E., Abbas W., Khan K.A., Tissot M., Jeudy A., Baud L., et al. Imbalance between HAT and HDAC activities in the PBMCs of patients with ankylosing spondylitis or rheumatoid arthritis and influence of HDAC inhibitors on TNF alpha production. PLoS One 2013, 8:e70939.
23. Tovar-Castillo L.E., Cancino-Díaz J.C., García-Vázquez F., Cancino-Gómez F.G., León-Dorantes G., Blancas-González F., et al. Under-expression of VHL and over-expression of HDAC-1, HIF-1alpha, LL-37, and IAP-2 in affected skin biopsies of patients with psoriasis. Int. J. Dermatol. 2007, 46:239-246.
24. Tsaprouni L.G., Ito K., Powell J.J., Adcock I.M., Punchard N. Differential patterns of histone acetylation in inflammatory bowel diseases. J. Inflamm. (Lond) 2011, 8:1.
25. Umezawa R., Yamada M., Horiguchi K., Ishii S., Hashimoto K., Okada S., et al. Aberrant histone modifications at the thyrotropin-releasing hormone gene in resistance to thyroid hormone: analysis of F455S mutant thyroid hormone receptor. Endocrinology 2009, 150:3425-3432.
26. Wang Y., Yang Y., Luo Y., Yin Y., Wang Q., Li Y., et al. Aberrant histone modification in peripheral blood B cells from patients with systemic sclerosis. Clin. Immunol. 2013, 149:46-54.
27. Wang Z., Zang C., Cui K., Schones D.E., Barski A., Peng W., et al. Genome wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell. 2009, 138:1019-1031.
28. Willis-Martinez D., Richards H.W., Timchenko N.A., Medrano E.E. Role of HDAC1 in senescence, aging, and cancer. Exp. Gerontol. 2010, 45:279-285.
29. Xia X.M., Zhao M., Ma J.Z., Fang X.L. Aberrant histone acetylation and methylation levels in woman with endometriosis. Arch. Gynecol. Obstet. 2013, 287:487-494.
30. Zhang P., Su Y., Zhao M., Huang W., Lu Q. Abnormal histone modifications in PBMCs from patients with psoriasis vulgaris. Eur. J. Dermatol. 2011, 21. 552-527.
31. Zhao M., Huang W., Zhang Q., Gao F., Wang L., Zhang G., et al. Aberrant epigenetic modifications in peripheral blood mononuclear cells from patients with pemphigus vulgaris. Br. J. Dermatol. 2012, 167:523-531.
32. Zhao M., Liang G., Wu X., Wang S., Zhang P., Su Y., et al. Abnormal epigenetic modifications in peripheral blood mononuclear cells from patients with alopecia areata. Br. J. Dermatol. 2012, 166:226-273.